Roche has entered into an agreement with Evotec to fund the Phase II clinical development of a selective N-methyl-D-aspartate (NMDA) receptor antagonist, EVT 101, for patients with treatment ...

BHV-5000 represents an important pharmacologic advance in the field of N-methyl-D-aspartate (NMDA) receptor antagonists as it is orally bioavailable and not associated with significant ...

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease ...

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

Axsome Therapeutics (AXSM) announced the completion of its Phase 3 clinical program evaluating AXS-05 a novel, oral, investigational NMDA ...

Hazwady Nazran, now 38, was hospitalised with mysterious and terrifying symptoms such as violent episodes, paranoid delusions, confusion, memory loss and seizures. If his wife, Dr Miria Hastuti ...

The results show a distinct distribution of NMDA receptors in the cortex of patients with Alzheimer's disease, where the number of synaptic NMDA receptors is significantly reduced, while ...

This is when antibodies produced by the immune system attack the brain’s own proteins, in this case its NMDA receptors. This receptor is involved in learning and memory, therefore sufferers ...

Shares of Axsome Therapeutics (AXSM) are under pressure on Monday after the company reported mixed results for a pair of studies of its ...